Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 114 articles: HTML format

Single Articles

March 2021
1. BURSTEIN HJ
   Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply.
   N Engl J Med. 2021;384:1176-1177.
   PubMed    
   
   
   
2. COPUR MS
   Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
   N Engl J Med. 2021;384:1176.
   PubMed    
   
   
   January 2021
3. DORLING L, Carvalho S, Allen J, Gonzalez-Neira A, et al
   Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
   N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa1913948.
   PubMed     Abstract available
   
   
   
4. NAROD SA
   Which Genes for Hereditary Breast Cancer?
   N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMe2035083.
   PubMed    
   
   
   
5. HU C, Hart SN, Gnanaolivu R, Huang H, et al
   A Population-Based Study of Genes Previously Implicated in Breast Cancer.
   N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa2005936.
   PubMed     Abstract available
   
   
   December 2020
6. BURSTEIN HJ
   Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
   N Engl J Med. 2020;383:2557-2570.
   PubMed    
   
   
   August 2020
7. O'DRISCOLL L
   When E-Cadherin Becomes Unstuck in Cancer.
   N Engl J Med. 2020;383:871-873.
   PubMed    
   
   
   July 2020
8. SPRING LM, Specht MC, Jimenez RB, Isakoff SJ, et al
   Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic.
   N Engl J Med. 2020 Jul 1. doi: 10.1056/NEJMcpc2002422.
   PubMed    
   
   
   June 2020
9. SCHMID P, Dent R, O'Shaughnessy J
   Pembrolizumab for Early Triple-Negative Breast Cancer. Reply.
   N Engl J Med. 2020;382:e108.
   PubMed    
   
   
   
10. CETIN B, Gumusay O
    Pembrolizumab for Early Triple-Negative Breast Cancer.
    N Engl J Med. 2020;382:e108.
    PubMed    
    
    
    
11. WINER EP
    Therapy for HER2-Positive Metastatic Breast Cancer. Reply.
    N Engl J Med. 2020;382:e98.
    PubMed    
    
    
    
12. DEKKER TJA
    Therapy for HER2-Positive Metastatic Breast Cancer.
    N Engl J Med. 2020;382:e98.
    PubMed    
    
    
    
13. SLAMON DJ, Jerusalem G
    Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply.
    N Engl J Med. 2020;382:e85.
    PubMed    
    
    
    
14. HINDIE E
    Ribociclib plus Fulvestrant in Advanced Breast Cancer.
    N Engl J Med. 2020;382:e85.
    PubMed    
    
    
    April 2020
15. MOLIERE S, Mathelin C
    The Cowden Syndrome.
    N Engl J Med. 2020;382:e29.
    PubMed    
    
    
    March 2020
16. BAKKER MF, de Lange SV, van Gils CH
    MRI Screening in Women with Dense Breasts. Reply.
    N Engl J Med. 2020;382:1284.
    PubMed    
    
    
    
17. WELCH HG, Zahl PH
    MRI Screening in Women with Dense Breasts.
    N Engl J Med. 2020;382:1283-1284.
    PubMed    
    
    
    
18. GORDON PB
    MRI Screening in Women with Dense Breasts.
    N Engl J Med. 2020;382:1283.
    PubMed    
    
    
    
19. AUTIER P
    MRI Screening in Women with Dense Breasts.
    N Engl J Med. 2020;382:1282.
    PubMed    
    
    
    
20. SHARMA V
    MRI Screening in Women with Dense Breasts.
    N Engl J Med. 2020;382:1282.
    PubMed    
    
    
    February 2020
21. SCHMID P, Cortes J, Pusztai L, McArthur H, et al
    Pembrolizumab for Early Triple-Negative Breast Cancer.
    N Engl J Med. 2020;382:810-821.
    PubMed     Abstract available
    
    
    
22. ISAKOFF SJ, Lehman CD, Shannon KM, Basnet KM, et al
    Case 7-2020: A 52-Year-Old Man with a Mass in the Left Breast.
    N Engl J Med. 2020;382:856-864.
    PubMed    
    
    
    
23. SHARMA P
    Major Strides in HER2 Blockade for Metastatic Breast Cancer.
    N Engl J Med. 2020;382:669-671.
    PubMed    
    
    
    January 2020
24. PINKERTON JV
    Hormone Therapy for Postmenopausal Women.
    N Engl J Med. 2020;382:446-455.
    PubMed    
    
    
    
25. HAYES DF
    Progress in the Treatment of Breast Cancer. Reply.
    N Engl J Med. 2020;382:e4.
    PubMed    
    
    
    
26. KONNER M
    Progress in the Treatment of Breast Cancer.
    N Engl J Med. 2020;382:e4.
    PubMed    
    
    
    December 2019
27. 
    Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    N Engl J Med. 2019 Dec 27. doi: 10.1056/NEJMx190039.
    PubMed    
    
    
    
28. SLAMON DJ, Neven P, Chia S, Fasching PA, et al
    Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
    N Engl J Med. 2019 Dec 11. doi: 10.1056/NEJMoa1911149.
    PubMed     Abstract available
    
    
    
29. MURTHY RK, Loi S, Okines A, Paplomata E, et al
    Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    N Engl J Med. 2019 Dec 11. doi: 10.1056/NEJMoa1914609.
    PubMed     Abstract available
    
    
    
30. MODI S, Saura C, Yamashita T, Park YH, et al
    Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
    N Engl J Med. 2019 Dec 11. doi: 10.1056/NEJMoa1914510.
    PubMed     Abstract available
    
    
    November 2019
31. LONGO DL
    Detecting Breast Cancer in Women with Dense Breasts.
    N Engl J Med. 2019;381:2169-2170.
    PubMed    
    
    
    
32. BAKKER MF, de Lange SV, Pijnappel RM, Mann RM, et al
    Supplemental MRI Screening for Women with Extremely Dense Breast Tissue.
    N Engl J Med. 2019;381:2091-2102.
    PubMed     Abstract available
    
    
    October 2019
33. IM SA, Lu YS, Tripathy D
    Ribociclib and Endocrine Therapy in Breast Cancer. Reply.
    N Engl J Med. 2019;381:1592-1593.
    PubMed    
    
    
    
34. ROCCA A, Melegari E, Palleschi M
    Ribociclib and Endocrine Therapy in Breast Cancer.
    N Engl J Med. 2019;381:1592.
    PubMed    
    
    
    September 2019
35. SPARANO JA
    Clinical and Genomic Risk in Adjuvant Therapy for Breast Cancer. Reply.
    N Engl J Med. 2019;381:1290-1291.
    PubMed    
    
    
    
36. GIORGI ROSSI P, Lebeau A, Schunemann HJ
    Clinical and Genomic Risk in Adjuvant Therapy for Breast Cancer.
    N Engl J Med. 2019;381:1289-1290.
    PubMed    
    
    
    
37. SCHVARTSMAN G, Kaliks RA
    Clinical and Genomic Risk in Adjuvant Therapy for Breast Cancer.
    N Engl J Med. 2019;381:1289-1291.
    PubMed    
    
    
    
38. SALINAS-BOTRAN A, Guarin-Corredor MJ
    Orbital Metastasis in Breast Cancer.
    N Engl J Med. 2019;381:e26.
    PubMed    
    
    
    
39. HAYES DF
    HER2 and Breast Cancer - A Phenomenal Success Story.
    N Engl J Med. 2019 Sep 10. doi: 10.1056/NEJMcibr1909386.
    PubMed    
    
    
    August 2019
40. ANDRE F, Mills D, Taran T
    Alpelisib for PIK3CA-Mutated Advanced Breast Cancer. Reply.
    N Engl J Med. 2019;381:687.
    PubMed    
    
    
    
41. COPUR MS, Jonglertham P
    Alpelisib for PIK3CA-Mutated Advanced Breast Cancer.
    N Engl J Med. 2019;381:686-687.
    PubMed    
    
    
    
42. PARK J, Shin SW
    Alpelisib for PIK3CA-Mutated Advanced Breast Cancer.
    N Engl J Med. 2019;381:686.
    PubMed    
    
    
    July 2019
43. RUGO HS
    Achieving Improved Survival Outcomes in Advanced Breast Cancer.
    N Engl J Med. 2019;381:371-372.
    PubMed    
    
    
    June 2019
44. HUNTER DJ, Longo DL
    The Precision of Evidence Needed to Practice "Precision Medicine".
    N Engl J Med. 2019;380:2472-2474.
    PubMed    
    
    
    
45. BARDIA A, Mayer IA, Kalinsky K
    Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2019;380:2382.
    PubMed    
    
    
    
46. OZAKI Y, Masuda J, Takano T
    Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:2382.
    PubMed    
    
    
    
47. 
    Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
    N Engl J Med. 2019;380:2282.
    PubMed    
    
    
    
48. IM SA, Lu YS, Bardia A, Harbeck N, et al
    Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
    N Engl J Med. 2019 Jun 4. doi: 10.1056/NEJMoa1903765.
    PubMed     Abstract available
    
    
    
49. SPARANO JA, Gray RJ, Ravdin PM, Makower DF, et al
    Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
    N Engl J Med. 2019 Jun 3. doi: 10.1056/NEJMoa1904819.
    PubMed     Abstract available
    
    
    May 2019
50. ANDRE F, Ciruelos E, Rubovszky G, Campone M, et al
    Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
    N Engl J Med. 2019;380:1929-1940.
    PubMed     Abstract available
    
    
    April 2019
51. WALKER SP
    The ROC Curve Redefined - Optimizing Sensitivity (and Specificity) to the Lived Reality of Cancer.
    N Engl J Med. 2019;380:1594-1595.
    PubMed    
    
    
    
52. PALLOK K, De Maio F, Ansell DA
    Structural Racism - A 60-Year-Old Black Woman with Breast Cancer.
    N Engl J Med. 2019;380:1489-1493.
    PubMed    
    
    
    
53. NARDI V
    Case 35-2018: A Woman with Back Pain and a Remote History of Breast Cancer. Reply.
    N Engl J Med. 2019;380.
    PubMed    
    
    
    
54. FOULKES WD, Witkowski L
    Case 35-2018: A Woman with Back Pain and a Remote History of Breast Cancer.
    N Engl J Med. 2019;380.
    PubMed    
    
    
    March 2019
55. MEHTA RS, Barlow WE, Albain KS, Vandenberg TA, et al
    Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
    N Engl J Med. 2019;380:1226-1234.
    PubMed     Abstract available
    
    
    
56. SCHMID P, Chui SY, Emens LA
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2019;380:987-988.
    PubMed    
    
    
    
57. ALTUNDAG K
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:986-987.
    PubMed    
    
    
    
58. O'SULLIVAN H, Collins D, O'Reilly S
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:986.
    PubMed    
    
    
    
59. AKTAS BY, Taban H, Aksoy S
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:985-986.
    PubMed    
    
    
    February 2019
60. MCCAW ZR, Vassy JL, Wei LJ
    Palbociclib and Fulvestrant in Breast Cancer.
    N Engl J Med. 2019;380:796.
    PubMed    
    
    
    
61. TURNER NC, Huang X, Cristofanilli M
    Palbociclib and Fulvestrant in Breast Cancer. Reply.
    N Engl J Med. 2019;380:797.
    PubMed    
    
    
    
62. NAIK RD, Batra A, Gupta VG
    Palbociclib and Fulvestrant in Breast Cancer.
    N Engl J Med. 2019;380:796.
    PubMed    
    
    
    
63. BARDIA A, Mayer IA, Vahdat LT, Tolaney SM, et al
    Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    N Engl J Med. 2019;380:741-751.
    PubMed     Abstract available
    
    
    
64. PROWELL TM, Beaver JA, Pazdur R
    Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer.
    N Engl J Med. 2019;380:612-615.
    PubMed    
    
    
    
65. HAYES DF
    Further Progress for Patients with Breast Cancer.
    N Engl J Med. 2019;380:676-677.
    PubMed    
    
    
    
66. 
    Lymphedema after Breast Cancer Treatment.
    N Engl J Med. 2019;380:694.
    PubMed    
    
    
    
67. JINDEEL A
    Lymphedema after Breast Cancer Treatment.
    N Engl J Med. 2019;380:694.
    PubMed    
    
    
    January 2019
68. DEFILIPPIS EM, Nohria A, Burstein HJ, Doyle LA, et al
    A Breath-Taking Diagnosis.
    N Engl J Med. 2019;380:81-87.
    PubMed    
    
    
    December 2018
69. 
    Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2018;379:2582.
    PubMed    
    
    
    
70. VON MINCKWITZ G, Huang CS, Mano MS, Loibl S, et al
    Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
    N Engl J Med. 2018 Dec 5. doi: 10.1056/NEJMoa1814017.
    PubMed     Abstract available
    
    
    November 2018
71. ROCKSON SG
    Lymphedema after Breast Cancer Treatment.
    N Engl J Med. 2018;379:1937-1944.
    PubMed    
    
    
    
72. BARDIA A, Hovnanian MD, Brachtel EF, Nardi V, et al
    Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer.
    N Engl J Med. 2018;379:1946-1953.
    PubMed    
    
    
    October 2018
73. CHLEBOWSKI RT, Pan K
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1684.
    PubMed    
    
    
    
74. PATEL A, Gupta VG
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683-4.
    PubMed    
    
    
    
75. LOVE RR
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683.
    PubMed    
    
    
    
76. NEWMAN LA
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1681-2.
    PubMed    
    
    
    
77. MCCAW ZR, Wei LJ, Kim DH
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1681.
    PubMed    
    
    
    
78. CHENG Y, Wu Y, Wu L
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1680-1.
    PubMed    
    
    
    
79. 
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683-1685.
    PubMed    
    
    
    
80. 
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1680-1682.
    PubMed    
    
    
    
81. SCHMID P, Adams S, Rugo HS, Schneeweiss A, et al
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2018 Oct 20. doi: 10.1056/NEJMoa1809615.
    PubMed     Abstract available
    
    
    
82. TURNER NC, Slamon DJ, Ro J, Bondarenko I, et al
    Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
    N Engl J Med. 2018 Oct 20. doi: 10.1056/NEJMoa1810527.
    PubMed     Abstract available
    
    
    
83. 
    Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations; Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2018;379:1585.
    PubMed    
    
    
    
84. 
    Breast Cancer in Men.
    N Engl J Med. 2018;379:1385-1386.
    PubMed    
    
    
    
85. KANAKIS GA, Jorgensen N, Goulis DG
    Breast Cancer in Men.
    N Engl J Med. 2018;379:1385.
    PubMed    
    
    
    August 2018
86. LITTON JK, Rugo HS, Ettl J, Hurvitz SA, et al
    Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    N Engl J Med. 2018 Aug 15. doi: 10.1056/NEJMoa1802905.
    PubMed     Abstract available
    
    
    July 2018
87. STEARNS V
    TAILORing Adjuvant Systemic Therapy for Breast Cancer.
    N Engl J Med. 2018;379:191-192.
    PubMed    
    
    
    June 2018
88. GIORDANO SH
    Breast Cancer in Men.
    N Engl J Med. 2018;378:2311-2320.
    PubMed    
    
    
    
89. MULASI I
    The Scarlet Virus.
    N Engl J Med. 2018;378:2157-2159.
    PubMed    
    
    
    
90. FRANCIS PA, Pagani O, Fleming GF, Walley BA, et al
    Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMoa1803164.
    PubMed     Abstract available
    
    
    
91. LIPPMAN ME
    Endocrine Adjuvant Therapy for Localized Breast Cancer.
    N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMe1806130.
    PubMed    
    
    
    
92. SPARANO JA, Gray RJ, Makower DF, Pritchard KI, et al
    Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
    N Engl J Med. 2018 Jun 3. doi: 10.1056/NEJMoa1804710.
    PubMed     Abstract available
    
    
    May 2018
93. ELMORE SNC
    p53 and Me.
    N Engl J Med. 2018;378:1962-1963.
    PubMed    
    
    
    March 2018
94. NACHTIGALL L, Naftolin F, Keefe DL
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1265.
    PubMed    
    
    
    
95. CRAMER DW, Braaten K
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264-8.
    PubMed    
    
    
    
96. ROBERTS K, Merkatz RB, Vieira CS
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    PubMed    
    
    
    
97. WOOD S
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    PubMed    
    
    
    
98. SCHWARZ EB, Foster DG, Grossman D
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-4.
    PubMed    
    
    
    
99. 
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-1266.
    PubMed    
    
    
    
100. 
     Breast-Cancer Recurrence after Stopping Endocrine Therapy.
     N Engl J Med. 2018;378:870-871.
     PubMed    
     
     
     
101. ANDERSON GM
     Breast-Cancer Recurrence after Stopping Endocrine Therapy.
     N Engl J Med. 2018;378:870.
     PubMed    
     
     
     January 2018
102. VAN DEN HEUVELEIBRINK MM, van der Kooi ALF, Wallace WHB
     Fertility Preservation in Women.
     N Engl J Med. 2018;378:399-400.
     PubMed    
     
     
     
103. DONNEZ J, Dolmans MM
     Fertility Preservation in Women.
     N Engl J Med. 2018;378:400-401.
     PubMed    
     
     
     December 2017
104. TURNER NC
     Signatures of DNA-Repair Deficiencies in Breast Cancer.
     N Engl J Med. 2017;377:2490-2492.
     PubMed    
     
     
     
105. MORCH LS, Skovlund CW, Hannaford PC, Iversen L, et al
     Contemporary Hormonal Contraception and the Risk of Breast Cancer.
     N Engl J Med. 2017;377:2228-2239.
     PubMed     Abstract available
     
     
     
106. DEMICHELE A, Yee D, Esserman L
     Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.
     N Engl J Med. 2017;377:2287-2289.
     PubMed    
     
     
     
107. HUNTER DJ
     Oral Contraceptives and the Small Increased Risk of Breast Cancer.
     N Engl J Med. 2017;377:2276-2277.
     PubMed    
     
     
     November 2017
108. PAN H, Gray R, Braybrooke J, Davies C, et al
     20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
     N Engl J Med. 2017;377:1836-1846.
     PubMed     Abstract available
     
     
     
109. NAROD S, Booth CM, Foulkes WD
     Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
     N Engl J Med. 2017;377:1792.
     PubMed    
     
     
     
110. OIDE T, Mitsuishi T
     Pigmented Macule - A Skin Manifestation of Invasive Breast Cancer.
     N Engl J Med. 2017;377:1777.
     PubMed    
     
     
     
111. 
     Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
     N Engl J Med. 2017;377:1792-3.
     PubMed    
     
     
     
112. GREENE AK, Voss SD, Maclellan RA
     Liposuction for Swelling in Patients with Lymphedema.
     N Engl J Med. 2017;377:1788-1789.
     PubMed    
     
     
     October 2017
113. LEMERY S, Keegan P, Pazdur R
     First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
     N Engl J Med. 2017;377:1409-1412.
     PubMed    
     
     
     September 2017
114. RAMASWAMI R, Morrow M, Jagsi R
     Contralateral Prophylactic Mastectomy.
     N Engl J Med. 2017;377:1288-1291.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: